FR13C0030I1 - Compositions pour le traitement de troubles gastrointestinaux - Google Patents

Compositions pour le traitement de troubles gastrointestinaux

Info

Publication number
FR13C0030I1
FR13C0030I1 FR13C0030C FR13C0030C FR13C0030I1 FR 13C0030 I1 FR13C0030 I1 FR 13C0030I1 FR 13C0030 C FR13C0030 C FR 13C0030C FR 13C0030 C FR13C0030 C FR 13C0030C FR 13C0030 I1 FR13C0030 I1 FR 13C0030I1
Authority
FR
France
Prior art keywords
compositions
treatment
gastrointestinal disorders
gastrointestinal
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR13C0030C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ironwood Pharmaceuticals Inc
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32854294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR13C0030(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of FR13C0030I1 publication Critical patent/FR13C0030I1/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
FR13C0030C 2003-01-28 2013-05-23 Compositions pour le traitement de troubles gastrointestinaux Active FR13C0030I1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US44309803P 2003-01-28 2003-01-28
US47128803P 2003-05-15 2003-05-15
US51946003P 2003-11-12 2003-11-12
EP04706011A EP1594517B1 (fr) 2003-01-28 2004-01-28 Compositions pour le traitement de troubles gastro-intestinaux
EP07011869A EP1911763B1 (fr) 2003-01-28 2004-01-28 Compositions pour le traitement de troubles gastrointestinaux

Publications (1)

Publication Number Publication Date
FR13C0030I1 true FR13C0030I1 (fr) 2013-07-05

Family

ID=32854294

Family Applications (2)

Application Number Title Priority Date Filing Date
FR13C0030C Active FR13C0030I1 (fr) 2003-01-28 2013-05-23 Compositions pour le traitement de troubles gastrointestinaux
FR13C0029C Active FR13C0029I2 (fr) 2003-01-28 2013-05-23 Compositions pour le traitement de troubles gastro-intestinaux

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR13C0029C Active FR13C0029I2 (fr) 2003-01-28 2013-05-23 Compositions pour le traitement de troubles gastro-intestinaux

Country Status (29)

Country Link
US (3) US20040266989A1 (fr)
EP (3) EP2246360B1 (fr)
JP (3) JP4584911B2 (fr)
KR (2) KR101227626B1 (fr)
CN (2) CN100589839C (fr)
AT (2) ATE477268T1 (fr)
AU (2) AU2004210161B2 (fr)
BE (1) BE2013C032I2 (fr)
BR (2) BR122018074353B8 (fr)
CA (1) CA2514507C (fr)
CY (5) CY1110905T1 (fr)
DE (2) DE602004028678D1 (fr)
DK (3) DK1594517T3 (fr)
ES (3) ES2387848T3 (fr)
FR (2) FR13C0030I1 (fr)
HK (1) HK1078768A1 (fr)
HU (1) HUS1300022I1 (fr)
IL (2) IL169863A (fr)
LT (1) LTC1594517I2 (fr)
LU (2) LU92200I2 (fr)
MX (1) MXPA05008097A (fr)
NL (1) NL300593I2 (fr)
NO (2) NO334112B1 (fr)
NZ (2) NZ541595A (fr)
PT (3) PT1911763E (fr)
RU (2) RU2353383C2 (fr)
SG (2) SG192300A1 (fr)
SI (3) SI1594517T1 (fr)
WO (1) WO2004069165A2 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2330312T5 (es) 2001-03-29 2014-01-31 Synergy Pharmaceuticals, Inc. Agonistas de receptor de guanilato ciclasa para el tratamiento de la inflamación de tejidos y de la carcionogénesis
US20060281682A1 (en) * 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
MXPA05008097A (es) 2003-01-28 2006-02-08 Microbia Inc Metodos y composiciones para el tratamiento de desordenes gastrointestinales.
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) * 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7494979B2 (en) * 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
EP3342420A1 (fr) * 2003-06-13 2018-07-04 Ironwood Pharmaceuticals, Inc. Procédé et compositions de traitement des troubles gastro-intestinaux
US20050266028A1 (en) * 2004-05-25 2005-12-01 University Of Georgia Research Foundation, Inc. Compositions and methods for modulating an immune response
WO2006046746A1 (fr) * 2004-10-26 2006-05-04 Ajinomoto Co., Inc. Agent préventif/thérapeutique pour des douleurs viscérales
CA2619650A1 (fr) * 2005-08-19 2007-02-22 Microbia, Inc. Compositions et methodes de traitement de troubles gastro-intestinaux
EP1937262B1 (fr) 2005-09-29 2019-05-08 Ipsen Pharma Composition pour l'utilisation dans le traitement de la dysmotilité gastrointestinale
CA2652677A1 (fr) * 2006-02-24 2007-09-07 Ironwood Pharmaceuticals, Inc. Methodes et compositions servant au traitement de troubles gastro-intestinaux
WO2008106429A2 (fr) * 2007-02-26 2008-09-04 Ironwood Pharmaceuticals, Inc. Procédés et compositions pour le traitement de l'insuffisance cardiaque et d'autres troubles
WO2008137318A1 (fr) * 2007-05-04 2008-11-13 Ironwood Pharmaceuticals, Inc. Compositions et procédés de traitement de troubles associés à la rétention de sel ou de fluide
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009149278A1 (fr) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
WO2010005515A2 (fr) * 2008-06-30 2010-01-14 Ironwood Pharmaceuticals Incorporated Procédés d’expression de protéines
EP2321341B1 (fr) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
CN102186490B (zh) * 2008-08-15 2015-07-29 硬木药品公司 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂
MX2011005245A (es) 2008-11-19 2011-06-17 Forest Lab Holdings Ltd Forma cristalina de linaclotida.
CA2745694C (fr) * 2008-12-03 2018-03-27 Synergy Pharmaceuticals, Inc. Formulations d'agonistes de guanylate cyclase c et methode d'utilisation
DK2417152T3 (da) 2009-04-10 2013-12-16 Corden Pharma Colorado Inc Fremgangsmåde til isolering af linaclotid
CA2770077A1 (fr) * 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprenant du linaclotide
RU2012109415A (ru) * 2009-08-13 2013-09-20 Айронвуд Фармасьютикалз, Инк. Способ модуляции фармакодинамического эффекта перорально вводимых агонистов рецептора гуанилатциклазы
US20140179607A9 (en) * 2009-11-09 2014-06-26 Ironwood Pharmaceuticals, Inc Treatments for Gastrointestinal Disorders
WO2011071927A2 (fr) 2009-12-07 2011-06-16 Ironwood Pharmaceuticals, Inc. Traitement des troubles gastro-intestinaux
TR201711271T4 (tr) 2010-02-17 2019-02-21 Ironwood Pharmaceuticals Inc Gastrointestinal Bozukluklar İçin Tedaviler
WO2011145062A1 (fr) 2010-05-21 2011-11-24 Link Research & Grants Corporation Traitement des acouphènes et de dysfonctions auditives apparentées
EP2605786A4 (fr) * 2010-06-09 2014-03-12 Combimab Inc Peptides thérapeutiques
PL2603232T3 (pl) 2010-08-11 2020-05-18 Ironwood Pharmaceuticals, Inc. Stabilne formulacje linaklotydu
AU2011302006A1 (en) 2010-09-15 2013-03-07 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase C agonists and methods of use
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012155114A1 (fr) 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Nouveaux dérivés d'uroguanyline et leur utilisation pour le traitement des troubles gastro-intestinaux
US9650417B2 (en) 2011-05-11 2017-05-16 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US9527887B2 (en) 2011-06-08 2016-12-27 Ironwood Pharmaceutical, Inc. Treatments for gastrointestinal disorders
US9617305B2 (en) 2011-06-08 2017-04-11 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
MD480Z5 (ro) * 2011-07-07 2012-09-30 Эльвира АНДОН Metodă de tratament al colitei ulceroase nespecifice acute
CN104053449B (zh) 2011-08-17 2016-12-07 硬木药品公司 胃肠疾患的治疗
EA022546B1 (ru) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Способ торможения роста карциномы эрлиха у лабораторного животного
US20140018307A1 (en) * 2012-07-12 2014-01-16 Forest Laboratories Holdings Ltd. Linaclotide compositions
RU2528641C2 (ru) * 2012-08-22 2014-09-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации Способ лечения больных с синдромом диспепсии в сочетании с избыточной массой тела
CN102875655B (zh) * 2012-09-29 2014-12-17 深圳翰宇药业股份有限公司 一种合成利那洛肽的方法
EP2950803A1 (fr) 2013-01-30 2015-12-09 Sandoz AG Forme cristalline de linaclotide
EP2970384A1 (fr) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
WO2015021358A2 (fr) 2013-08-09 2015-02-12 Dominique Charmot Composés et procédés d'inhibition du transport de phosphate
LT3288578T (lt) * 2015-05-01 2023-04-25 Ironwood Pharmaceuticals, Inc. Kompozicijos, skirtos gaubtinės žarnos valymui ir virškinimo trakto sutrikimų gydymui
EP3430056A4 (fr) * 2016-03-15 2019-11-20 The Regents of the University of California Méthodes et compositions pour traiter et prévenir des maladies associées à l'intégrine alpha 8 beta 1
CN107929718A (zh) * 2017-10-19 2018-04-20 南京星银药业集团有限公司 Glp‑1类似物及gc‑c受体激动剂组合物缓释制剂及其制备方法
EP3870263A4 (fr) * 2018-10-23 2022-08-03 ABK Biomedical Incorporated Dispositif d'administration
CN109467606A (zh) * 2018-11-15 2019-03-15 大连理工大学 一种大肠杆菌肠毒素STa-LTB-STb融合蛋白及其编码基因和应用
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport
RU2712761C1 (ru) * 2019-07-02 2020-01-31 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство для стимуляции регенерации эндотелия легких при сочетании метаболического синдрома и хронической обструктивной болезни легких
CN111265653B (zh) * 2020-02-09 2023-05-09 华中科技大学同济医学院附属协和医院 心房利钠肽在制备炎症性肠病治疗药物中的应用
WO2021191865A1 (fr) * 2020-03-26 2021-09-30 Dusa Pharmaceuticals, Inc. Gestion de lésions de la neurofibromatose dermique
WO2023144292A1 (fr) 2022-01-28 2023-08-03 Fresenius Kabi Ipsum S.R.L. Procédé de préparation de linaclotide

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US232013A (en) * 1880-09-07 Henry h
US32684A (en) * 1861-07-02 Stump-extkactob
US73628A (en) * 1868-01-21 mitchell
US266989A (en) * 1882-11-07 Automatic fire
US258687A (en) * 1882-05-30 Grain-binder
US152868A (en) * 1874-07-07 Improvement in type-setting machines
US121961A (en) * 1871-12-19 Improvement in devices for supporting pipe-cores
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US6342373B1 (en) * 1983-11-21 2002-01-29 Ucp Gen-Pharma Ag Process for preparing recombinant eglin, protease inhibitor
IT1217123B (it) 1987-02-05 1990-03-14 Rotta Research Lab Derivati otticamente attivi dell acido 5 pentilammino 5 oxo pentanoico r ad attivita antagonista della colecistochinina e procedimento per la loro preparazione
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
CH679207A5 (fr) 1989-07-28 1992-01-15 Debiopharm Sa
CA2046830C (fr) 1990-07-19 1999-12-14 Patrick P. Deluca Systeme d'administration des medicaments comprenant une interaction entre une proteine ou une polypeptide et un polymere hydrophobe biodegradable
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
FR2674849B1 (fr) 1991-04-02 1994-12-23 Logeais Labor Jacques Nouveaux derives de n-cyclohexyl benzamides ou thiobenzamides, leurs preparations et leurs applications en therapeutique.
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5140102A (en) 1991-09-23 1992-08-18 Monsanto Company Pentadecapeptide, guanylin, which stimulates intestinal guanylate cyclase
PL171920B1 (pl) * 1991-12-02 1997-06-30 Cor Therapeutics Inc Sposób wytwarzania nowego, hamujacego PDGF-R polipeptydy immunoglobulinowego PL
EP0625162B1 (fr) 1991-12-30 1998-05-13 Neurex Corporation Procedes servant a induire l'analgesie et a favoriser l'analgesie par opiaces
US5824645A (en) 1991-12-30 1998-10-20 Neurex Corporation Method of treating inflammation
GB9211268D0 (en) 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5969097A (en) * 1992-06-23 1999-10-19 G. D. Searle & Co. Human guanylin
PT678018E (pt) 1993-01-06 2003-08-29 Kinerton Ltd Conjugados moleculares ionicos de poliesteres biodegradaveis e de polipeptidos bioactivos
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5395490A (en) * 1993-05-14 1995-03-07 Intertec, Ltd. Method for treating materials by the application of electromagnetic energy at resonant absorption frequencies
CA2174928C (fr) * 1993-10-26 2011-08-16 Scott A. Waldman Compositions se fixant specifiquement a des cellules cancereuses colo-rectales et procedes d'utilisation
US5489670A (en) * 1993-10-29 1996-02-06 G. D. Searle & Co. Human uroguanylin
US5610145A (en) 1994-04-15 1997-03-11 Warner-Lambert Company Tachykinin antagonists
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5795864A (en) 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
US6054429A (en) 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
ATE359086T1 (de) 1995-06-27 2007-05-15 Eisai R&D Man Co Ltd Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen
GB9524104D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
CA2238298A1 (fr) 1995-11-24 1997-06-19 Luca Francesco Raveglia Derives de quinoline
WO1997040085A2 (fr) 1996-04-23 1997-10-30 Kinerton Limited Polymeres polylactiques acides
US6589750B2 (en) 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
DE59814173D1 (de) 1997-02-28 2008-04-03 Nycomed Gmbh Synergistische kombination von pde-hemmern und adenylatcyclase-agonisten bzw. guanylcyclyse-agonisten
US5893985A (en) 1997-03-14 1999-04-13 The Lincoln Electric Company Plasma arc torch
NZ329807A (en) 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
WO1999014239A1 (fr) 1997-09-12 1999-03-25 Wolf Georg Forssmann Composition pour le traitement du diabete sucre et de l'obesite
US20010006972A1 (en) 1998-04-21 2001-07-05 Stephen A. Williams Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
IT1304152B1 (it) 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
DK1185294T3 (da) 1999-06-23 2005-08-01 Centre Nat Rech Scient Peptider til behandling af svækkede interpersonelle og adfærdsmæssige lidelser
CN1164334C (zh) 1999-08-18 2004-09-01 研究及应用科学协会股份有限公司 肽的缓释制剂
SE9903291D0 (sv) 1999-09-15 1999-09-15 Astra Ab New process
EP1220872A1 (fr) 1999-10-06 2002-07-10 Pharmacia Corporation Uroguanyline, anticancereux intestinal
CA2389650C (fr) 1999-11-01 2008-12-09 Rodeva Limited Composition destinee au traitement de la constipation et du syndrome du colon irritable
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
WO2001064212A1 (fr) 2000-03-01 2001-09-07 University College London Modulateurs de l'absorption d'endocannabinoide et des recepteurs de vallinoide
ATE288763T1 (de) 2000-12-22 2005-02-15 Pasteur Institut Prozess zum screening von molekülen, die spezifisch an die nep-bindungsstelle des qhnpr- pentapeptides binden
JP2004521123A (ja) 2001-02-02 2004-07-15 ファルマシア・コーポレーション 腸癌阻害のためのウログアニリンおよびシクロオキシゲナーゼ−２阻害薬の組合わせ
ES2330312T5 (es) * 2001-03-29 2014-01-31 Synergy Pharmaceuticals, Inc. Agonistas de receptor de guanilato ciclasa para el tratamiento de la inflamación de tejidos y de la carcionogénesis
EP1451211A2 (fr) 2001-03-30 2004-09-01 University of Copenhagen Compositions et procedes de modulation de l'activite du recepteur signalant la guanylyl cylclase et de traitement de la maladie de meniere
MY134211A (en) 2001-05-18 2007-11-30 Smithkline Beecham Corp Novel use
EP1392729A2 (fr) * 2001-06-05 2004-03-03 Yalcin Cetin Utilisation d'un peptide qui active la guanylate-cyclase c pour le traitement de maladies des voies respiratoires par les voies aeriennes, medicament, dispositif d'inhalation et methode de diagnostic
FR2830451B1 (fr) 2001-10-09 2004-04-30 Inst Nat Sante Rech Med Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur
EP1321142A1 (fr) 2001-12-21 2003-06-25 Novartis AG Forme solide pour l'administration orale du Tégaserode
US20040121961A1 (en) 2002-02-04 2004-06-24 Jaime Masferrer Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
US20030232013A1 (en) 2002-02-22 2003-12-18 Gary Sieckman Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
AU2003224644A1 (en) 2002-02-27 2003-09-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
JP2005526079A (ja) 2002-03-15 2005-09-02 サイプレス バイオサイエンス， インコーポレイテッド 内蔵痛症候群を処置するためのｎｅおよび５−ｈｔ再取り込み阻害剤
JP2005531557A (ja) 2002-05-17 2005-10-20 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 選択的オピエート受容体モジュレーターとして効果的な化合物の使用
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
MXPA05008097A (es) 2003-01-28 2006-02-08 Microbia Inc Metodos y composiciones para el tratamiento de desordenes gastrointestinales.
US7371727B2 (en) * 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20060281682A1 (en) 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
EP1599165A4 (fr) 2003-02-10 2010-09-08 Univ Jefferson Utilisation de ligands gcc
CA2619650A1 (fr) 2005-08-19 2007-02-22 Microbia, Inc. Compositions et methodes de traitement de troubles gastro-intestinaux

Also Published As

Publication number Publication date
RU2005127058A (ru) 2006-03-10
HUS1300022I1 (hu) 2019-11-28
DK1911763T3 (da) 2010-11-15
DE602004007105T2 (de) 2008-02-28
LU92201I2 (fr) 2013-11-22
ES2387848T3 (es) 2012-10-02
US20090005534A1 (en) 2009-01-01
CA2514507A1 (fr) 2004-08-19
CY1111058T1 (el) 2015-06-11
DE602004007105D1 (de) 2007-08-02
IL221380A0 (en) 2012-09-24
SI1911763T1 (sl) 2010-11-30
CY1113217T1 (el) 2016-04-13
AU2009235993B2 (en) 2013-07-04
CY1110905T1 (el) 2015-06-10
AU2009235993A1 (en) 2009-11-26
CN101787073B (zh) 2013-12-25
CN101787073A (zh) 2010-07-28
IL169863A (en) 2012-10-31
DK2246360T3 (da) 2012-08-13
BE2013C032I2 (fr) 2023-08-22
NL300593I2 (nl) 2020-04-15
BR122018074353B8 (pt) 2023-05-02
LTC1594517I2 (lt) 2020-03-10
WO2004069165A3 (fr) 2005-03-17
AU2004210161A1 (en) 2004-08-19
NO336768B1 (no) 2015-11-02
BR122018074353B1 (pt) 2019-07-16
PT2246360E (pt) 2012-08-31
JP2006516631A (ja) 2006-07-06
HK1078768A1 (en) 2006-03-24
ATE365174T1 (de) 2007-07-15
BRPI0407071B1 (pt) 2019-02-12
EP1911763A2 (fr) 2008-04-16
RU2543350C2 (ru) 2015-02-27
RU2763796C2 (ru) 2022-01-11
LU92200I1 (fr) 2020-06-02
US8080526B2 (en) 2011-12-20
RU2008147983A (ru) 2010-06-10
RU2014153593A3 (fr) 2018-08-06
ES2285417T3 (es) 2007-11-16
NZ541595A (en) 2008-08-29
EP1594517A2 (fr) 2005-11-16
FR13C0029I1 (fr) 2013-07-05
JP4584911B2 (ja) 2010-11-24
FR13C0029I2 (fr) 2024-04-19
EP1594517A4 (fr) 2006-03-29
NZ570134A (en) 2010-02-26
LU92200I2 (fr) 2024-03-21
CY2013021I1 (el) 2020-05-29
US20110124583A1 (en) 2011-05-26
KR101227627B1 (ko) 2013-01-31
PT1594517E (pt) 2007-07-20
AU2004210161B2 (en) 2009-11-26
DK1594517T3 (da) 2007-10-29
EP2246360B1 (fr) 2012-06-27
RU2353383C2 (ru) 2009-04-27
SI2246360T1 (sl) 2012-10-30
EP2246360A1 (fr) 2010-11-03
CN100589839C (zh) 2010-02-17
CY2013022I1 (el) 2020-05-29
NO20130460L (no) 2005-10-26
JP5748791B2 (ja) 2015-07-15
SG168407A1 (en) 2011-02-28
EP1911763B1 (fr) 2010-08-11
RU2014153593A (ru) 2016-07-20
WO2004069165A2 (fr) 2004-08-19
US7704947B2 (en) 2010-04-27
KR101227626B1 (ko) 2013-02-01
KR20110114682A (ko) 2011-10-19
CA2514507C (fr) 2012-03-20
MXPA05008097A (es) 2006-02-08
JP2010222377A (ja) 2010-10-07
BRPI0407071B8 (pt) 2021-05-25
EP1911763A3 (fr) 2008-06-25
ES2350123T3 (es) 2011-01-18
JP2013116910A (ja) 2013-06-13
PT1911763E (pt) 2010-11-18
JP5563384B2 (ja) 2014-07-30
US20040266989A1 (en) 2004-12-30
ATE477268T1 (de) 2010-08-15
SG192300A1 (en) 2013-08-30
SI1594517T1 (sl) 2007-10-31
BRPI0407071A (pt) 2006-01-24
EP1594517B1 (fr) 2007-06-20
DE602004028678D1 (de) 2010-09-23
NO20053864L (no) 2005-10-26
KR20050106404A (ko) 2005-11-09
NO334112B1 (no) 2013-12-09
CN1795007A (zh) 2006-06-28
NO20053864D0 (no) 2005-08-18
NL300593I1 (nl) 2015-10-21

Similar Documents

Publication Publication Date Title
FR13C0029I2 (fr) Compositions pour le traitement de troubles gastro-intestinaux
MA28791B1 (fr) Derives de piperazine convenant pour le traitement de troubles gastro-intestinaux
MA28481B1 (fr) Dérivés d'imidazole pour le traitement de troubles neurodégénératifs
IL178730A0 (en) New pharmaceutical compositions for the treatment of sexual disorders ii
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
MA29098B1 (fr) Compositions pour le traitement du vhc
IL179674A0 (en) Chemical compounds and pharmaceutical compositions containing them for the treatment of inflammatory disorders
PT1644021E (pt) Métodos e composições para o tratamento de distúrbios gastrointestinais
FR22C1033I1 (fr) Utilisation de dihydroimidazolones pour le traitement des chiens
ZA200606804B (en) Pharmaceutical composition for treatment of immunological disorders
FR2854074B1 (fr) Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
MA28493B1 (fr) Sulfonamides destinés au traitement de troubles neurodégénératifs
IL162485A0 (en) Compounds for the treatment of inflammatory disorders
EP1658072A4 (fr) Composes pour le traitement de maladies neurodegeneratives
MA29085B1 (fr) Agent prophylactique ou thérapeutique pour le traitement des troubles du sommeil
FR2860154B1 (fr) Composition pour le traitement de la mauvaise haleine
FR2835851B1 (fr) Composition pour le traitement d'alliages de magnesium
FR2924593B1 (fr) Plaque osseuse pour le traitement de l'extremite inferieure du cubitus
IL160852A0 (en) Pharmaceutical compositions for the treatment of urinary disorders
FR2884714B1 (fr) Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires
FR2868312B1 (fr) Patch pour le traitement des levres
ZA200607463B (en) New pharmaceutical compositions for the treatment of sexual disorders II
MA28513B1 (fr) Processus pour la preparation d'inhibiteurs de tryptase
HK1094698A1 (en) Beta-lactams for the treatment of cns disorders
FR2851247B1 (fr) Methodes et compositions pour le traitement de pathologies degeneratives oculaires